Navigation Links
De nouvelles directives recommandent la fidaxomicine pour tous les patients pouvant suivre un traitement antibiotique par voie orale pour une infection à Clostridium difficile
Date:10/29/2013

est une étape importante pour la réduction de la morbidité et de la mortalité associée à l'ICD », déclare le professeur Oliver Cornely de l'hôpital universitaire de Cologne en Allemagne. « J'approuve ces directives et je pense que l'application de ces recommandations améliorera le traitement de l'ICD et réduira le fardeau à la fois pour les patients et les systèmes de santé. »

Deux importantes études cliniques de phase III comparant l'efficacité et l'innocuité de 400 mg par jour fidaxomicine par voie orale à 500 mg par jour de vancomycine ont permis de montrer les avantages potentiels de la fidaxomicine par rapport à la vancomycine qui est le traitement habituel.[9],[11] Les patients participant à ces essais présentaient un diagnostic confirmé d'ICD et incluaient des patients classés comme souffrant d'une ICD grave ainsi que des patients pour lesquels l'ICD constituait un risque particulièrement important comme les personnes âgées[11] ou avec des pathologies concomitantes.[12],[13],[14] La fidaxomincine a permis de réduire considérablement le taux de récurrence de l'ICD comparé à la vancomycine et les patients traités avec la fidaxomicine étaient plus susceptibles de ne plus souffrir de diarrhées sans récurrence 30 jours après la fin du traitement, que les patients traités avec de la vancomycine.[9],[11] La fidaxomicine a également atteint son critère d'évaluation principal de taux de guérison clinique qui était équivalent à celui de la vancomycine.[9],[11]

Certaines populations courent un risque plus élevé d'ICD et sont particulièrement vulnérables. L'ICD peut être as
'/>"/>

SOURCE Astellas Pharma Europe Ltd
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Medicare Procurement Program Creates Extreme Hardships For North Carolina Patients, Says AAHomecare
2. Strong Efficacy Data Prompt Charleston Laboratories to Halt Phase 3 Study of CL-108 in Patients with Moderate to Severe Acute Pain
3. Lumena Pharmaceuticals Initiates the CLARITY Phase II Study of LUM001 in Patients with Primary Biliary Cirrhosis
4. 3SBio to Develop DJ5 for Progressive Renal Failure in ADPKD Patients
5. Juventas Therapeutics completes enrollment of Phase II STOP-HF study of JVS-100 in patients with symptomatic heart failure
6. Medicare Procurement Program Creates Extreme Hardships for Patients without Options, Says AAHomecare
7. Media Sourcerys Secure Mobile Workflow App Deployed by CCS Medical to Expedite Product Delivery to Patients
8. Lamotrigine is One of the Most Commonly Prescribed Drugs Among Newly Diagnosed Bipolar Disorder Patients in the United States
9. Among Newly Diagnosed Type 2 Diabetes Patients, DPP-IV Inhibitors are the Leading Oral Therapies After Standard Metformin and Sulfonylurea
10. Should Mircera Reach the U.S. Market, Surveyed Nephrologists State that at Least 40 Percent of CKD-ND and Dialysis Patients are Likely Candidates
11. Ampio Pharmaceuticals subsidiary Luoxis Diagnostics announces positive summary data from study of traumatic brain injury patients and issuance of companys third US patent for its oxidation-reduction potential diagnostic platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ... the fourth quarter of 2013 on Monday, February 3, 2014. ... after the close of trading. (Logo: ... to discuss the operating highlights and financial results for the ...
(Date:1/14/2014)... 2014 Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company ... Progressive Home Medical Equipment, Inc. ("Progressive") of Clarion, ... the acquisition were not disclosed. Progressive is ... wide range of sleep, mobility, and respiratory products to customers ...
(Date:1/14/2014)... PLYMOUTH, Minn. , Jan. 14, 2014   NuAire , a ... come to agreement with Hitachi Koki of ... centrifuges in North America . NuAire will utilize ... and Canada to offer assistance ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
... Be Presented --, SAN FRANCISCO, April 24, 2007 /PRNewswire-FirstCall/ ... Phase,2 efficacy study of Dimebon(TM) in Alzheimer's disease will ... at the American,Academy of Neurology's 59th Annual Meeting in ... The presentation will include new,data from both the mild ...
... WIRE)--Apr 24, 2007 - Ceragenix Pharmaceuticals,Inc. (OTCBB:CGXP) ... study comparing EpiCeram's(TM) efficacy to,that of Cutivate(R) ... of moderate-to-severe atopic dermatitis (AD)., The study, ... of 113,pediatric patients, with 59 patients receiving ...
Cached Medicine Technology:Medivation Announces First U.S. Presentation of Data From Dimebon,Phase 2 Alzheimer's Disease Trial at American Academy of Neurology,Annual Meeting 2Medivation Announces First U.S. Presentation of Data From Dimebon,Phase 2 Alzheimer's Disease Trial at American Academy of Neurology,Annual Meeting 3Ceragenix Announces Results from Phase IV Study of EpiCeram Meet,All Primary and Secondary Endpoints 2Ceragenix Announces Results from Phase IV Study of EpiCeram Meet,All Primary and Secondary Endpoints 3Ceragenix Announces Results from Phase IV Study of EpiCeram Meet,All Primary and Secondary Endpoints 4Ceragenix Announces Results from Phase IV Study of EpiCeram Meet,All Primary and Secondary Endpoints 5Ceragenix Announces Results from Phase IV Study of EpiCeram Meet,All Primary and Secondary Endpoints 6
(Date:4/23/2014)... from Sub-Saharan Africa, Latin America and Caribbean islands ... new research from St. Michael,s Hospital. , The ... of Obstetrics and Gynaecology , assessed the differences ... native-born women in six high-immigration countries Australia ... Valencia) and the United States (California, New Jersey ...
(Date:4/23/2014)... director at the National Institute of Arthritis and Musculoskeletal ... recipient of the Ross Prize in Molecular Medicine, conferred ... Medicine . The award will be given on June ... Manhattan, followed by scientific presentations by Dr. O,Shea and ... Institutes of Health. , The award, which includes a ...
(Date:4/23/2014)... report that rats exposed to high-energy particles, simulating conditions ... show lapses in attention and slower reaction times, even ... ranges. , The cognitive impairments which affected a ... appear to be linked to protein changes in ... to hold true in humans, suggest it may be ...
(Date:4/23/2014)... N.Y. A novel compound that targets an important ... of cocaine addiction behaviors, including relapse behavior, a University ... provides strong evidence that this may be a novel ... effective medications exist., The UB research was published as ... week. , In the study, the compound, RO5263397, severely ...
(Date:4/23/2014)... new computer program could help doctors predict which patients ... treatment. , The program, which assesses brain scans ... airport security and passport control, has been developed by ... study funded by the Wellcome Trust, which used the ... . , Stroke affects over 15 million people ...
Breaking Medicine News(10 mins):Health News:Pregnancy complications may be more common in immigrants from certain regions 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:Airport security-style technology could help doctors decide on stroke treatment 2Health News:Airport security-style technology could help doctors decide on stroke treatment 3
... ... every year, 35 to 50 million Americans become infected with the flu (influenza). On average, ... Plano, TX is taking steps to combat these preventable deaths by offering free flu shots ... Plano, TX (Vocus) September 12, ...
... , , , ... important safety notice to its more than 750,000 subscribers of its ... wearing a "pendant" style help button. The service is used primarily ... at risk of falls. By pressing a "help button" worn on ...
... of Public Health has been awarded $18.4 million by ... U.S. Department of Defense to establish an Extremity Trauma ... the coordinating center for the Consortium that includes a ... with several major military treatment centers and the U.S. ...
... ... on the Failed War on Drugs , ... Las Vegas, NV (PRWEB) September 11, 2009 -- PAINWeek® 2009, the national conference ... drug reform in the United States as keynote speaker former Assistant US Attorney Jennifer Bolen, ...
... help predict who,s susceptible to the disease, study says , ... to a higher risk of Alzheimer,s disease seems to affect ... thought, new research suggests. , The brains of people in ... -- which boosts the risk of Alzheimer,s but doesn,t guarantee ...
... , NEW YORK, Sept. 11 Duane Reade Holdings ... that, as the Local Presenting Sponsor of the 2009 Komen New ... its foundation, The Duane Reade Charitable Foundation, have raised $330,000 to ... to find a cure. This marks the third year that Duane ...
Cached Medicine News:Health News:H1N1 frenzy may allow regular flu to be more deadly than ever 2Health News:Lifeline Issues Safety Notice to Subscribers 2Health News:JHSPH to lead extremity trauma clinical research consortium 2Health News:JHSPH to lead extremity trauma clinical research consortium 3Health News:Healthcare Legal Issues Take the Stage at PAINWeek 2009 2Health News:Healthcare Legal Issues Take the Stage at PAINWeek 2009 3Health News:Alzheimer's Gene Affects Brains of Young Adults 2Health News:New Yorkers Help Duane Reade Increase Support of the 19th Annual Komen New York City Race For The Cure(R) 2Health News:New Yorkers Help Duane Reade Increase Support of the 19th Annual Komen New York City Race For The Cure(R) 3
... of Hemoglobin S in patient samples. Each ... and 20l of anticoagulated whole blood or ... test kit contains two bottles of phosphate ... and two vials of Sodium Hydrosulfite reagent ...
... CD-Chex Plus BC is an assayed control ... systems. CD-Chex Plus BC determines the accuracy ... in the process of immunophenotyping, including red ... subsets of leukocytes include: T lymphocytes, B ...
Streck-T-Pack is specially designed for use on Coulter® Counter T Series instruments. Each convenient pack includes diluent, lysing agent and enzymatic cleanser. The shelf life is 18 months from ...
... CD-Chex CD34 is a ... leukocytes which can be used ... when evaluating CD34 positive cells. ... ISHAGE and ProCOUNT gating strategies. ...
Medicine Products: